ALN-PCS

11/06/2023 - "Serious adverse events of Inclisiran in patients with hypercholesterolemia, a meta analysis of ORION trials."
07/01/2023 - "[ANMCO Position paper: Inclisiran: an innovative therapeutic approach for the clinical management of hypercholesterolemia]."
03/01/2023 - "Inclisiran: A Review in Hypercholesterolemia."
07/01/2021 - "Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? "
05/01/2021 - "This review aims to focus on the role of inclisiran in the management of hypercholesterolemia."

01/01/2023 - "Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease."
08/01/2022 - "Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease."
01/01/2022 - "Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease."
01/01/2022 - "Which patients at risk of cardiovascular disease might benefit the most from inclisiran? "
12/01/2021 - "An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease."

01/01/2023 - "Review of article: Inclisiran for the treatment of heterozygous familial hypercholesterolemia. "
01/01/2020 - "Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia."
01/01/2021 - "Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis."
11/01/2020 - "This key paper evaluation focuses on Phase 3 trials that assess inclisiran in the treatment of hypercholesterolemia and heterozygous familial hypercholesterolemia. "
11/01/2018 - "The ongoing ORION program includes Phase III trials that will provide robust evidence of inclisiran's safety and efficacy in individuals at high risk of atherosclerotic cardiovascular disease (ASCVD), including established ASCVD and familial hypercholesterolemia. "

08/01/2018 - "To date, inclisiran has been effective in treating hyperlipidemia. "
08/01/2018 - "Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials."
01/20/2023 - "The Cochrane Library, EMBASE, PubMed, CNKI, WANGFANG database, VIP database, ClinicalTrials.gov, and ICRT were searched electronically to collect SRs and meta-analysis of Inclisiran in hyperlipidemia treatment from the establishment of the database till May 2022. "
01/20/2023 - "This paper aimed to comprehensively evaluate the effectiveness and safety of Inclisiran in treating hyperlipidemia through an overview of systematic reviews (SRs). "
01/20/2023 - "Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews."

01/01/2022 - "Data from the clinical trials in the ORION program demonstrated efficacy and safety of inclisiran in patients with dyslipidemia. "
01/01/2022 - "Although the combination of efficacy and safety makes inclisiran a good option for the treatment of dyslipidemia compared to other PCSK9 targeting therapeutic strategies, however, further studies should exclude the possibility that inclisiran, through lower-affinity interactions, may influence other mRNAs in the physiological milieu."
01/01/2022 - "This paper aims to review the mechanism of action of inclisiran while evaluating its efficacy and safety in the treatment of dyslipidemia from data of the clinical trials in the ORION program. "
01/01/2023 - "Inclisiran: a novel drug for the treatment of dyslipidemia."
05/01/2021 - "Inclisiran in dyslipidemia."